TNFRSF1B and graft versus host disease: Conclusively, therapeutically targeting of TNFR2 in patients appears as a highly promising approach to either propagate donor Tregs in vitro or, importantly, to enhance Treg activity by expanding TNFR2+ Tregs in patients before allo-HCT to prevent GvHD.